| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE38919 | PROVENSIS | Injectable microfoam containing a sclerosing agent |
Oct, 2014
(9 years ago) | |
| USRE40640 | PROVENSIS | Injectable microfoam containing a sclerosing agent |
Oct, 2016
(7 years ago) | |
| US7604185 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US8734833 | PROVENSIS | Therapeutic foam |
May, 2020
(3 years ago) | |
| US8323677 | PROVENSIS | Therapeutic foam |
May, 2020
(3 years ago) | |
| US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7357336 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US7025290 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US6572873 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US7842282 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US7842283 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US6942165 | PROVENSIS | Generation of therapeutic microfoam |
May, 2020
(3 years ago) | |
| US6846412 | PROVENSIS | Combination filter assembly |
Jul, 2022
(1 year, 9 months ago) | |
| US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(4 months from now) | |
| US7814943 | PROVENSIS | Apparatus and method for dispensing foam |
Nov, 2027
(3 years from now) | |
| US9480652 | PROVENSIS | Aerosol valve |
May, 2032
(8 years from now) | |
Varithena is owned by Provensis.
Varithena contains Polidocanol.
Varithena has a total of 16 drug patents out of which 12 drug patents have expired.
Expired drug patents of Varithena are:
- US7357336
- US7025290
- US6572873
- US7842282
- US7842283
- US6942165
- US6846412
- USRE38919
- USRE40640
- US7604185
- US8734833
- US8323677
Varithena was authorised for market use on 21 December, 2017.
Varithena is available in solution;intravenous dosage forms.
Varithena can be used as a method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the knee, a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities, a method of generating an injectable foam of controlled density and bubble size.
The generics of Varithena are possible to be released after 12 May, 2032.
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 21 December, 2017
Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins ...
Dosage: SOLUTION;INTRAVENOUS
VARITHENA family patents
